RNA - Avidity Biosciences, Inc.

QQQ $ 473.14 $ -2.10 (-0.44 %)

DIA $ 417.33 $ 2.44 (0.59 %)

SPY $ 562.48 $ 0.83 (0.15 %)

TLT $ 101.29 $ 0.92 (0.92 %)

GLD $ 238.61 $ -0.02 (-0.01 %)

Previous Close

$ 41.75

Open

$ 42.07

Bid

$ 41.72 x 200

Ask

-- x --

Day's Range

$ 41.16 - $ 42.40

52 Week Range

$ 4.83 - $ 48.80

Volume

994,317

Average Volume

Market Cap

4.58B

Beta (5Y Monthly)

$ 1.20

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-09-2024	06-30-2024	10-Q
2	05-09-2024	03-31-2024	10-Q
3	02-28-2024	12-31-2023	10-K
4	11-08-2023	09-30-2023	10-Q
5	08-08-2023	06-30-2023	10-Q
6	05-09-2023	03-31-2023	10-Q
7	02-28-2023	12-31-2022	10-K
8	11-08-2022	09-30-2022	10-Q
9	08-09-2022	06-30-2022	10-Q
10	05-10-2022	03-31-2022	10-Q
11	03-01-2022	12-31-2021	10-K
12	11-09-2021	09-30-2021	10-Q
13	08-09-2021	06-30-2021	10-Q
14	05-12-2021	03-31-2021	10-Q
15	03-15-2021	12-31-2020	10-K
16	11-10-2020	09-30-2020	10-Q
17	08-11-2020	06-30-2020	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Unveiling 7 Analyst Insights On Avidity Bi...
09/16/2024 19:00:26

Cantor Fitzgerald Reiterates Overweight on...
09/16/2024 17:01:11

Cantor Fitzgerald analyst Eric Schmidt reiterates Avidity Biosciences (NASDAQ:RNA) with a Overweight and maintains $96 price...

fulcrum-therapeutics-upgraded-bofa-debates-pivotal-study-success-for-losmapimod-in-rare-genetic-muscle-disease

Fulcrum Therapeutics Upgraded: BofA Debate...
09/09/2024 18:28:05

BofA Securities upgraded Fulcrum Therapeutics ahead of its phase 3 losmapimod results for Facioscapulohumeral muscular dystroph...

Cantor Fitzgerald Reiterates Overweight on...
09/09/2024 16:08:41

Cantor Fitzgerald analyst Eric Schmidt reiterates Avidity Biosciences (NASDAQ:RNA) with a Overweight and maintains $96 price...

Deep Dive Into Avidity Biosciences Stock: ...
08/28/2024 13:00:18

Barclays Initiates Coverage On Avidity Bio...
08/28/2024 12:28:32

Barclays analyst Gena Wang initiates coverage on Avidity Biosciences (NASDAQ:RNA) with a Overweight rating and announces Pri...

Evercore ISI Group Maintains Outperform on...
08/26/2024 13:14:51

Evercore ISI Group analyst Josh Schimmer maintains Avidity Biosciences (NASDAQ:RNA) with a Outperform and lowers the price t...

Reported Earlier, Avidity Biosciences Pric...
08/15/2024 07:00:26

The gross proceeds to Avidity from the offering, before deducting the underwriting discounts and commissions and other offering...

Avidity Biosciences Proposes $250M Public ...
08/13/2024 20:24:15

Avidity Biosciences, Inc. (NASDAQ:RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics cal...

Needham Reiterates Buy on Avidity Bioscien...
08/13/2024 10:11:14

Needham analyst Joseph Stringer reiterates Avidity Biosciences (NASDAQ:RNA) with a Buy and maintains $60 price target.

The Analyst Landscape: 7 Takes On Avidity ...
08/12/2024 16:00:29

Evercore ISI Group Maintains Outperform on...
08/12/2024 14:04:12

Evercore ISI Group analyst Josh Schimmer maintains Avidity Biosciences (NASDAQ:RNA) with a Outperform and raises the price t...

Chardan Capital Maintains Buy on Avidity B...
08/09/2024 21:52:25

Chardan Capital analyst Keay Nakae maintains Avidity Biosciences (NASDAQ:RNA) with a Buy and raises the price target from $4...

Avidity Biosciences Q2 EPS $(0.65) Beats $...
08/09/2024 20:12:37

Avidity Biosciences (NASDAQ:RNA) reported quarterly losses of $(0.65) per share which beat the analyst consensus estimate of $(...

Expedia Posts Upbeat Earnings, Joins Akama...
08/09/2024 16:51:33

Avidity Biosciences Says Data Suggest del-...
08/09/2024 11:15:59

AOC 1044 demonstrated favorable safety and tolerability. Avidity also announced delpacibart zotadirsen as the approved internat...

genedx-leads-russell-2000-this-year-as-it-shifts-to-more-comprehensive-genetic-testing-corrected

GeneDx Leads Russell 2000 This Year As It ...
08/02/2024 18:06:16

GeneDx Holdings Corp. (NASDAQ: WGS) has soared 1,101% this year, attributed to its mix shift towards exome/genome testing and r...

GeneDx Leads Russell 2000 This Year As It ...
08/02/2024 18:06:16

GeneDx Holdings Corp. (NASDAQ: WGS) has soared 1,101% this year, attributed to its mix shift towards exome/genome testing and r...

top-performing-industry-etfs-in-june-software-leads-returns-chipmakers-attract-most-inflows

Top Performing Industry ETFs In June: Soft...
07/01/2024 17:38:29

June saw gains in the U.S. stock market, with tech and biotech leading the way. Semiconductor ETFs saw strong inflows, while ut...

rna---analyzing-avidity-biosciencess-short-interest

(RNA) - Analyzing Avidity Biosciences's Sh...
06/20/2024 15:45:19